A Phase 1 Expansion Cohort Evaluating the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Unresectable Melanoma

Trial Profile

A Phase 1 Expansion Cohort Evaluating the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Unresectable Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Selinexor (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jul 2017 Planned primary completion date changed from 31 Jul 2017 to 31 Jul 2018.
    • 11 Jul 2017 Status changed from suspended to recruiting.
    • 06 Jun 2017 Preliminary results (n=7, as of Jan 2017), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top